{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Treatment+C&page=3", "query": { "intervention": "Placebo for Treatment C", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 673, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Treatment+C&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Treatment+C&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T07:56:29.830Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05956509", "title": "Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Upper Limb Spasticity" ], "interventions": [ { "name": "ABBV-950", "type": "BIOLOGICAL" }, { "name": "BOTOX", "type": "BIOLOGICAL" }, { "name": "Placebo for ABBV-950", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1, "start_date": "2024-01-12", "completion_date": "2024-06-02", "has_results": false, "last_update_posted_date": "2024-07-01", "last_synced_at": "2026-10-08T07:56:29.830Z", "location_count": 9, "location_summary": "Carlsbad, California • Downey, California • Fresno, California + 6 more", "locations": [ { "city": "Carlsbad", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05956509" }, { "nct_id": "NCT02368899", "title": "Computerized Alcohol Misuse Intervention System for Health Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alcoholism" ], "interventions": [ { "name": "Computerized Alcohol Misuse Intervention", "type": "OTHER" }, { "name": "Attention Control (AC)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Research Circle Associates, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2016-11", "completion_date": "2017-04-17", "has_results": false, "last_update_posted_date": "2017-05-10", "last_synced_at": "2026-10-08T07:56:29.830Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02368899" }, { "nct_id": "NCT00326898", "title": "Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Stage I Renal Cell Cancer AJCC v6 and v7", "Stage II Renal Cell Cancer AJCC v7", "Stage III Renal Cell Cancer AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Sorafenib Tosylate", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1943, "start_date": "2006-04-24", "completion_date": "2021-09-01", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-08T07:56:29.830Z", "location_count": 966, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 601 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00326898" }, { "nct_id": "NCT01482403", "title": "A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "boceprevir", "type": "DRUG" }, { "name": "mericitabine", "type": "DRUG" }, { "name": "mericitabine placebo", "type": "DRUG" }, { "name": "boceprevir placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2011-11", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2016-08-05", "last_synced_at": "2026-10-08T07:56:29.830Z", "location_count": 7, "location_summary": "Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more", "locations": [ { "city": "Littleton", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482403" }, { "nct_id": "NCT05322590", "title": "BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Carcinoma", "Neuropathy" ], "interventions": [ { "name": "BXQ-350", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 195, "start_date": "2023-01-09", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-08T07:56:29.830Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05322590" }, { "nct_id": "NCT05800015", "title": "A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "fianlimab", "type": "DRUG" }, { "name": "cemiplimab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2023-08-08", "completion_date": "2031-12-23", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-08T07:56:29.830Z", "location_count": 29, "location_summary": "Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05800015" }, { "nct_id": "NCT01004978", "title": "Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma", "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Doxorubicin-Eluting Beads", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mitomycin", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Sorafenib Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2009-10-28", "completion_date": "2022-12-21", "has_results": true, "last_update_posted_date": "2024-01-03", "last_synced_at": "2026-10-08T07:56:29.830Z", "location_count": 281, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 183 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004978" }, { "nct_id": "NCT02053350", "title": "Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clostridium Difficile Infection" ], "interventions": [ { "name": "Alanyl-glutamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2015-04", "completion_date": "2017-04-05", "has_results": true, "last_update_posted_date": "2022-06-07", "last_synced_at": "2026-10-08T07:56:29.830Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02053350" }, { "nct_id": "NCT02115724", "title": "Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiovascular Disease" ], "interventions": [ { "name": "Antioxidant cocktail", "type": "DIETARY_SUPPLEMENT" }, { "name": "Biopsy", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "NMD; 0.4mg sub-lingual nitroglycerin spray", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER", "DRUG" ], "sponsor": "Augusta University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 74, "start_date": "2014-04", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-10-08T07:56:29.830Z", "location_count": 1, "location_summary": "Augusta, Georgia", "locations": [ { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02115724" }, { "nct_id": "NCT05637879", "title": "Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "PTSD" ], "interventions": [ { "name": "Glecaprevir/pibrentasvir", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "White River Junction Veterans Affairs Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "19 Years to 70 Years" }, "enrollment_count": 92, "start_date": "2023-12-18", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-10-08T07:56:29.830Z", "location_count": 1, "location_summary": "White River Junction, Vermont", "locations": [ { "city": "White River Junction", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT05637879" } ] }